Akèy › Obèsite › Arizona › Tucson
Etid klinik pou Obèsite nan Tucson, AZ
17 etid pou Obèsite ap chèche patisipan nan sit nan ak bò kote Tucson (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event
Ap rekriteFaz 2
- Pima Heart, Tucson
- Eclipse Clinical Research, Tucson
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
Ap rekriteFaz 3
- University of Arizona, Tucson
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
Ap rekriteFaz 3
- Tucson Clinical Research Institute, Tucson
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
Ap rekriteFaz 3
- Novak Clinical Research - Tucson - North La Cholla Boulevard, Tucson
A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight
Ap rekriteFaz 3
- Research Site, Tucson
Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
Ap rekriteFaz 3
- Tucson Orthopaedic Institute - North Wyatt Drive, Tucson
A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
Ap rekriteFaz 2
- The Institute for Liver Health II dba Arizona Liver Health-Tucson, Tucson
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
Ap rekriteFaz 3
- AURORA-1 Clinical Site, Tucson
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
Ap rekriteFaz 3
- AURORA-2 Clinical Site, Tucson
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
Ap rekriteFaz 3
- Pima Heart and Vascular Clinical Research, Tucson
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
Ap rekriteFaz 3
- Arizona Clinical Trials, Tucson
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
Ap rekriteFaz 3
- Arizona Clinical Trials, Tucson
A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
Ap rekriteFaz 3Volontè an sante akeyi
- ACCOMPLISH-2 Research Site, Tucson
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
Ap rekriteFaz 2
- The Institute for Liver Health II dba Arizona Liver Health-Tucson, Tucson
A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes
Ap rekriteFaz 2
- Pima Heart, Tucson
Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
Ap rekriteFaz 3
- ACCOMPLISH-1 Research Site, Tucson
A Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepatitis (MASLD/MASH)
Ap rekriteFaz 1/2
- Adobe Clinical Research, Tucson
Etid Obèsite nan lòt vil
- Houston, TX43 etid
- Chicago, IL41 etid
- New York City, NY40 etid
- San Antonio, TX40 etid
- Washington, DC33 etid
- Orlando, FL31 etid
- Dallas, TX30 etid
- Boston, MA28 etid
- Las Vegas, NV27 etid
- Miami, FL27 etid
- Baltimore, MD25 etid
- Jacksonville, FL25 etid
Lòt etid nan Tucson
- Kansè nan tete20 etid
- Kansè Poumon ki pa ti selil17 etid
- Sipwa15 etid
- Kansè Metastatik14 etid
- Kansè (tout kalite)12 etid
- Maladi kadyovaskilè12 etid
- Kansè kolorektal11 etid
- Kansè pwostat11 etid
- Maladi fwa steatotik10 etid
- Ensifizyans kadyak10 etid
- Hypertension artérielle10 etid
- Dyabèt Tip 210 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.